[Cytokine in cancer chemotherapy--clinical trials of IL-3, IL-11 and thrombopoietin against thrombocytopenia].
Clinical trials of IL-3, IL-11 and thrombopoietin (TPO) against chemotherapy-induced thrombocytopenia were reviewed. Many clinical trials of IL-3 were conducted, which increased the platelet nadir counts and improved the recovery from thrombocytopenia at a dose of 5 micrograms/kg/day for 7 to 14 days. Major side effects, fever and headache, were tolerable. The combination with G-CSF was also examined. IL-11 improved the platelet nadir counts and the recovery from thrombocytopenia at a dose of 50 micrograms/kg/day for 14 days. Adverse events of IL-11 were general fatigue and edema, which were mild. Phase I/II studies of TPO were conducted, which showed a marked increase of platelet counts and improvement in recovery from thrombocytopenia. A few patients experienced mild thrombo-embolism. Improved QOL and survival benefits in the evaluation of these cytokines must be demonstrated.
Kudoh
S
S
First Dept. of Internal Medicine, Osaka City University Medical School.
Yamada
M
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D016190:Carboplatin / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000188:drug therapy; D002986:Clinical Trials as Topic; D017322:Clinical Trials, Phase II as Topic; D004334:Drug Administration Schedule; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D017370:Interleukin-11 / Q000008:administration & dosage*; D007377:Interleukin-3 / Q000008:administration & dosage*; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy; D017239:Paclitaxel / Q000009:adverse effects; D010976:Platelet Count; D016032:Randomized Controlled Trials as Topic; D013921:Thrombocytopenia / Q000139:chemically induced / Q000628:therapy*; D013926:Thrombopoietin / Q000008:administration & dosage; D014481:United States
D017370:Interleukin-11; D007377:Interleukin-3; D016179:Granulocyte Colony-Stimulating Factor; D013926:Thrombopoietin; D016190:Carboplatin; D017239:Paclitaxel